GlassScriptPhysician profile
Michael B Collins
NPI 1326127267
$2,903.19
in general payments reported to CMS, 2019-2025
21 companies · $780 in 2025
The $780 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $76.00 · 2021: $39.46 · 2022: $260 · 2023: $144 · 2024: $331 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,083.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $341.47 | 2022-2025 | |
| Asahi Intecc USA, INC. | $183.07 | 2024-2025 | Asahi Coronary Wires, Asahi Peripheral Vascular Wires, Peripheral Vascular |
| Heartflow, INC. | $161.66 | 2025 | |
| Medtronic, INC. | $160.08 | 2022 | |
| Abiomed | $141.93 | 2025 | |
| Boston Scientific Corporation | $141.11 | 2024 | Avvigo Guidance System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.14 | 2020-2025 | Jardiance |
| Regeneron Pharmaceuticals, INC. | $115.00 | 2025 | |
| Medtronic Vascular, INC. | $102.97 | 2019 | |
| Cardiovascular Systems INC. | $91.90 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.79 | 2019-2023 | Lifevest |
| Amgen INC. | $37.28 | 2020-2023 | Repatha |
| Alnylam Pharmaceuticals INC. | $29.50 | 2025 | Amvuttra |
| Biosense Webster, INC. | $25.34 | 2023 | Carto 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.70 | 2022 | |
| Bridgebio Pharma, INC. | $22.54 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $21.70 | 2021 | |
| Chiesi USA, INC. | $16.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.25 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.